Cite
HARVARD Citation
Wicki, A. et al. (2018). First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). European journal of cancer. pp. 6-16. [Online].